BERLIN, Germany and NEW YORK, USA, January 06, 2022 / B3C newswire / ProBioGen AG is delighted to announce the execution of a service and commercial product license agreement with Imvaq Therapeutics, a biotech company developing innovative cancer immunotherapies. Under this agreement, ProBioGen develops a scalabl.
ProBioGen and LAVA Therapeutics N V Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
BERLIN, Germany and CAIRO, Egypt, May 27, 2021 / B3C newswire / ProBioGen and Minapharm Pharmaceuticals announce the incorporation of ProBioGen's subsidiary "MiGenTra" with headquarters in Berlin and access to a site in Cairo, which will house its principal manufacturing plant. The formati.
Asher Biotherapeutics Contracts ProBioGen to Develop and Manufacture Their Lead Candidate
BERLIN, Germany, April 26, 2021 / B3C newswire / ProBioGen AG today announced that Asher Biotherapeutics, Inc., has entered into a service agreement covering all aspects of cell line development, process development and GMP manufacturing at 1000 L bioreactor scale.
ProBioGen will now advance the development of Asher s lead candidate in immuno-oncology applying its unique transposase technology DirectedLuck™ which greatly accelerates time-to-clinic.
Asher Biotherapeutics, a biotech company located in the San Francisco Bay Area, is developing cis-targeted immunotherapies with a new level of selectivity for the potential treatment of cancer, autoimmune and infectious diseases.
ProBioGen Licenses GlymaxX® Technology to AbbVie
Search jobs
ADCC-Enhancement for Innovative Therapies
BERLIN, Germany, January 21, 2021 / B3C newswire / ProBioGen AG has signed a commercial license agreement with AbbVie for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).
The proven GlymaxX
® technology for production of afucosylated proteins is universally applicable, simple and potent. The unique advantage of the GlymaxX
® technology is that a single GlymaxX
® modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation level. The technology can easily be integrated in newly developed or already existing cell lines of different origins.